Trilegal and CMS INDUSLAW have acted as legal counsel on the Iswarya Fertility Center OrbiMed investment, a primary funding round worth ₹355 crore (approximately $37 million). The deal marks the maiden institutional capital raise for one of India’s largest fertility care networks. Trilegal advised the investee and its promoters, while CMS INDUSLAW represented the investor.
Introduction
Iswarya Health Private Limited, the parent company of Iswarya Fertility Center, has secured a primary investment of ₹355 crore from OrbiMed Asia VI Mauritius Limited, an investment vehicle of OrbiMed. The transaction constitutes Iswarya’s first institutional capital raise, making it a landmark event in the company’s four-decade history. The capital will be deployed to strengthen clinical capabilities, expand the company’s centre footprint, and broaden access to fertility care across India.
Founded in 1986, Iswarya Fertility Center has grown into a nationwide fertility network with 87+ centres across India. The organisation has served over 300,000 couples through advanced fertility treatments and reproductive healthcare services over its history. The promoters of Iswarya Health Private Limited are Dr. Arun Muthuvel, Dr. S. Chandralekha, and Dr. K. Veluswamy.
OrbiMed is a global healthcare-focused investment firm operating across life sciences and medical services. The investment was channelled through its vehicle, OrbiMed Asia VI Mauritius Limited.
Deal Value
The transaction involved a primary investment of ₹355 crore (approximately $37 million). The investment marks Iswarya’s first institutional capital raise. Further financial terms were not disclosed.
Legal Teams Involved
Trilegal — Advised Iswarya Health Private Limited and its Promoters
- Rahul Chugh — Partner (transaction lead)
- Kriti Chatrath — Senior Associate
- Samridhi Poddar — Associate
CMS INDUSLAW — Advised OrbiMed
Kartik Ganapathy (Founding and Senior Partner) provided strategic inputs on certain aspects of the transaction.
The core advisory team comprised:
- Aakash Dasgupta — Partner
- Ravin Abhyankar — Senior Associate
- Anshul Bhuwalka — Senior Associate
- Saumya Joshi — Associate
Shantanu Jindel (Partner) advised on the regulatory aspects of the transaction.
Due diligence assistance was provided by:
- Aanshavi Srishti — Associate
- Abhinav A — Associate
- Suryanshu Mishra — Associate
- Samarth Jain — Associate
Corporate Secretarial aspects were advised upon by:
- Ruhi Jain — Executive Director
- Praveen Hegde — Manager
- Adarsh Joshi — Assistant Manager
Intellectual Property aspects were advised upon by:
- Bharadwaj Jaishankar — Partner
- Trushita Mehra — Senior Associate
Significance and Impact
This transaction is significant for several reasons. It represents Iswarya Fertility Center’s first-ever institutional capital raise, signalling the organisation’s transition from a promoter-led growth model to one backed by institutional private equity. The scale of the investment — ₹355 crore from a globally recognised healthcare-focused fund — underscores growing investor confidence in India’s fertility care sector.
The deal also demonstrates the breadth of legal advisory work involved in complex healthcare private equity transactions in India. The CMS INDUSLAW team spanned corporate, regulatory, intellectual property, and corporate secretarial practices, reflecting the multi-disciplinary nature of such investments. For Trilegal, the mandate involved representing not only the corporate entity but also its three individual promoters, adding a further layer of advisory complexity.
From a sectoral standpoint, the investment is expected to accelerate Iswarya’s pan-India expansion, with plans to establish new centres in existing and underserved markets, strengthen clinical infrastructure, and expand the embryology talent pipeline. The transaction positions Iswarya to address India’s growing demand for quality fertility care — a segment that remains significantly underpenetrated relative to need.
For a running record of significant India-focused legal deals, see the Deal Meter.
The ₹355 crore primary investment by OrbiMed Asia VI Mauritius Limited into Iswarya Health Private Limited stands as one of the more consequential healthcare private equity transactions in India’s fertility care segment. Trilegal and CMS INDUSLAW provided comprehensive legal coverage across all aspects of the deal. The transaction sets the stage for Iswarya Fertility Center’s next phase of institutional-grade growth across India.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. It is based on the details provided and publicly available sources.
